The Food and Drug Administration has given Lupin the green light for azilsartan medoxomil tablets in dosage strengths of 40 mg and 80 mg.
The medication is the generic of Azurity’s Edarbi, an angiotensin II receptor blocker that may be prescribed alone or taken along with other medications used to treat high blood pressure.
The product will be manufactured at Lupin’s facility in Nagpur, India.
Azilsartan medoxomil tablets had a market value of roughly $101 million, according to March 2022 IQVIA data.
[Read more: FDA approves 3 Lupin generics]